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doi:10.1016/j.jmii.2011.04.008Background: Caffeic acid phenethyl ester (CAPE), an active component of propolis, has been
proven to have anti-inflammatory and antiallergic properties. We have investigated the
activity of CAPE in regulating cytokine-induced eotaxin production and its related signal
protein, signal transducer and activator of transcription 6 (STAT6), in human lung fibroblast.
Methods: The CCD-11Lu human lung fibroblast cell line was used as an in vitro model. Cells
were pretreated with CAPE followed by stimulation with interleukin-4 and tumor necrosis
factor alpha. The levels of eotaxin in cultured supernatants were measured by enzyme-
linked immunosorbent assay. The amounts of STAT6 and phosphorylated STAT6 in cellular
nuclear protein extracts were determined by Western blot analysis. STAT6 DNA binding
activities were detected by electrophoretic mobility shift assay.
Results: Pretreated CCD-11Lu cells with noncytotoxic doses (0.1e10 mM) of CAPE inhibited
the production of eotaxin under stimulation of interleukin-4 (10 ng/mL) and tumor necrosis
factor alpha (10 ng/mL). CAPE pretreatment also decreased the amount of phosphorylated
STAT6 and the STAT6 DNA binding complexes in nuclear extracts.
Conclusion: CAPE inhibited the production of eotaxin protein in stimulated human lung fibro-
blast cells in a dose-dependent manner. This activity is, at least, through STAT6 inhibition.
We suggest that CAPE is a promising agent in controlling eotaxin secretion and subsequentof Pediatrics, Taichung Veterans General Hospital, No. 160, Section 3, Chung-Kang Road, Taichung
com.tw (L.-S. Fu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
436 Y.-T. Lin et al.eosinophils influx and may therefore have a potential role to play in treating allergic airway
disease.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Asthma is a chronic inflammatory condition of the airways
resulting in episodic airflow obstruction, airway hyper-
responsiveness, and airway remodeling. Asthmatic airway
tissues have increased numbers of activated eosinophils,
neutrophils, mast cells, and activated lymphocytes, espe-
cially Type 2 T helper (Th2) cells.1e3 Massive accumulation
of eosinophils in airways is a fundamental trait of bronchial
asthma.4 Eosinophils and their products, including cyto-
toxic granule proteins and de novo synthesized leukotri-
enes, are important effectors in the pathophysiology
of airway allergic inflammation, causing destruction of
airway epithelium, sensitization of airway nerve terminals,
vascular leakage, and other pathological changes.5 Th2
lymphocytes and their products, such as interleukin (IL)-4,
IL-5, and IL-13, mediated the airway eosinophil infiltration
and IgE production,6 and are known to stimulate the
expression of several chemokines and mediators, such as
eotaxin.7,8 These chemokines may favor the recruitment of
Th2 cells, eosinophils, basophils, and mast cells into the
airway,9 which lead to chronic airway inflammation.
Eotaxin, a potent chemokine for eosinophil, was origi-
nally discovered in 1994, has an important local role in the
recruitment of eosinophils from the microvasculature into
the tissue at sites of local allergic inflammation.10e12
Eotaxin can be produced by many cell types, including
lung fibroblast, smooth muscle cell, endothelial cell, alve-
olar macrophage, eosinophil, lymphocyte, and bronchial
epithelial cell.13 Among them, fibroblast is the major
cellular source of eotaxin.14,15 Several studies revealed that
the combination of IL-4 and tumor necrosis factor alpha
(TNF-a) could amplify the production of eotaxin in human
lung fibroblast, airway epithelial cell, smooth muscle cell,
and dermal fibroblast.7,9,16e19 The mechanism operative in
regulating IL-4 and TNF-a-stimulated eotaxin expression in
epithelial cell and human lung fibroblast was mediated by
activation of transcription factors, NF-kappa B (NF-kB)
and signal transducer and activator of transcription 6
(STAT6).16,17
Caffeic acid phenethyl ester (CAPE) is a bioactive
component of propolis (honeybee resin), which has several
biological properties including anti-inflammatory, antioxi-
dant, antimicrobial, and antitumor activities.20 More
recently, in murine model of ovalbumin-induced asthma,
CAPE had significant effects on inhibition of characteristic
asthmatic reactions (inflammatory cells; cytokines IL-4,
IL-5, and TNF-a; mucus hypersecretion; and serum oval-
bumin-specific IgE), diminished reactive oxygen species in
bronchoalveolar fluid, and NF-kB DNA binding activity.21
Although the eotaxin promoter contains overlapping
consensus bindings sites for transcription factors, NF-kB
and STAT6 are known to mediate responses to IL-4 and
TNF-a.17 Data showed that both IL-4 and TNF-a requireSTAT6 as mediator to activate eotaxin gene expression in
fibroblast cells.19
In our previous study,22 we demonstrated that CAPE can
inhibit eotaxin secretion in human lung fibroblast (CCD-
11Lu cell line) stimulated synergistically by IL-13 and
TNF-a. We also showed that CAPE was able to inhibit NF-kB
activation. The aim of present study is to check if CAPE
possesses inhibitory effect on STAT6 activation.
Methods
Reagents
CAPE was purchased from Calbiochem (San Diego, CA, USA)
and dissolved in dimethyl sulfoxide (Merck, Darmstadt,
Germany) in a stock concentration of 10 mM. Recombinant
human IL-4 and TNF-a were purchased from Peprotech
(Rocky Hill, NJ, USA). Eotaxin sandwich ELISA kits were
purchased from BD biosciences (San Jose, CA, USA).
Cells and culture medium
The human lung fibroblast cell line, CCD-11Lu, was
purchased from American Type Culture Collection (Mana-
ssas, VA, USA). The cells were cultured in minimum essential
medium (Gibco-BRL, Rockville, MD, USA) containing 10%
heat-inactivated fetal bovine serum, 100 units/mL of peni-
cillin, and 100 mg/mL of streptomycin (Invitrogen, Carlsbad,
CA, USA) in a humidified 5% carbon dioxide/95% air atmo-
sphere at 37C.
Cell culture and study design
We cultured cells under the following conditions:
1. Cells (1 105cells/well) were seeded in each well of
12-well plates (BD biosciences, San Jose, CA, USA) to
settle and adhere for 24 hours. The culture medium was
removed and replaced by serum-free medium, then the
confluent monolayer were incubated with recombinant
human IL-4 (10 ng/mL, 50 ng/mL), TNF-a (10 ng/mL,
50 ng/mL), or the combination of different concentra-
tion in the dose range 10 ng/mL and 50 ng/mL for 24
hours. Cells without stimulation were used as negative
control. The supernatants were harvested and
conserved at 80C.
2. We pretreated cell under condition (1) with CAPE of
various concentration (0.1 mM, 1 mM, 10 mM) for 3 hours
(which is the earliest effective time of CAPE on eotaxin
production in our preliminary study), followed by the
stimulation with recombinant human IL-4 (10 ng/mL)
and TNF-a (10 ng/mL) for another 24 hours. The
supernatants were harvested and conserved at 80C.
Suppression of CAPE in human lung fibroblast cells 4373. Cells (5 106cells/flask) were seeded in each 75-cm2 T
flask (Nunc, Rockilde, Denmark) to settle and adhere
for 24 hours. The culture medium was removed and
replaced by serum-free medium, then the confluent
monolayer were pretreated with CAPE of various
concentration (0.01 mM, 0.1 mM, 1 mM) for 3 hours, fol-
lowed by the stimulation with recombinant human IL-4
(10 ng/mL) and TNF-a (10 ng/mL) for another 45
minutes. The cells were washed with ice-cold Dulbec-
co’s phosphate buffered saline (Gibco-BRL, USA) to stop
the biological activity, and then the cells were
collected for nuclear/cytoplasmic extraction.Figure 1. The survival curves of CCD-11Lu cells. CCD-11Lu
human lung fibroblast cells were incubated with CAPE
(0.1 mM, 1 mM, 10 mM) for 3 hours with or without followed by
IL-4 (10 ng/mL) and TNF-a (10 ng/mL) for additional 24 hours.
Then, the survival assay was performed. The survival of CCD-
11Lu cells were all more than 90% when comparing with the
negative control group. CAPEZ caffeic acid phenethyl ester;
IL-4Z interleukin-4; TNF-aZ tumor necrosis factor alpha.Cell survival
Cell survival was measured based on the ability of mito-
chondrial enzymes in living cells to chemically reduce
a tetrazolium salt (MTT) into a colored formazan dye as
previously described.23 The 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) was purchased from
Serva Electrophoresis GmbH (Heidelberg, Germany).
Chemokine assays
The concentration of eotaxin in the previous prepared
supernatants in condition (1) and (2) were quantified with
the use of a commercially available ELISA kit (BD Biosci-
ences) according to the manufacturer’s instructions.
Absorbance was read at 450 nm with ELISA reader (Thermo
Labsystems, Waltham, MA, USA).
Preparation of nuclear/cytoplasmic extracts
The nuclear and cytoplasmic extracts were prepared by using
an NE-PER nuclear and cytoplasmic extraction kit (Pierce,
Rockford, IL, USA). We followed the experimental protocol
offered by the manufacturer. The CCD-11Lu cells prepared
in condition (3) were resuspended in hypotonic buffer
(provided in NE-PER kit). The homogenates were centrifuged
and the supernatants were collected as cytoplasmic
extracts. The nuclear pellets were resuspended in extraction
buffer (provided in NE-PER kit). After been incubated in ice
for 40 minutes, the nuclear extracts were collected. All
fractions of proteins mentioned previously were identified
and quantified by Bradford method (Dc Protein Assay,
Bio-Rad, Hercules, CA, USA), and stored at 80C.
Western blot analysis
We followed the standard method.22 All membranes were
incubated with the following antibody overnight at 4C with
continuous shaking: mouse monoclonal antihuman STAT6
antibody (1:250 BD biosciences) and mouse monoclonal
antihuman phosphorylated STAT6 (p-STAT6) (pY641) anti-
body (1:500 Abcam, Cambridge, UK). We detected prolifer-
ating cell nuclear antigen by mouse monoclonal antihuman
antibody (1:5,000 Abcam) as internal control. The intensities
of the pixels within each immunoreactive band were quan-
titated on an odyssey infrared (IR) imaging system associatedwith Odyssey software (version 1.2) according to the manu-
facturer (Li-Cor Biosciences, Lincoln, NE).
Electrophoresis mobility shift assay
Nuclear extracts (20mg protein) were mixed with Odyssey IR
electrophoresis mobility shift assay Kit (LI-COR, Inc.,
Lincoln, NE) according to the manufacturer’s instructions.
The IR dye-labeled STAT6 oligonucleotide (50-IRDye800-
GCTCTTCTTCCCAGGAACTCAATG; 30-CGAGAAGAAGGGTCC
TTGAGTTAC-IRdye 800-50) was prepared as Ohmori’s
methods24 and then added to the protein mixture and
incubated at room temperature in the dark for 30 minutes.
The protein-DNA complexes were separated by electro-
phoresis through 5% native polyacrylamide gels at 70 V for
1 hour in Tris-borate-EDTA buffer in the dark. Electropho-
resis mobility shift assayA gels were analyzed using the
LI-COR Odyssey IR laser imaging system.
Statistical analysis
All results were represented as the means standard error
of the mean of at least three independent experiments.
Statistical analyses were performed using Mann-Whitney U
test to compare data. A probability value (p) less than 0.05
was considered statistically significant difference.
Results
Cell viability studies
The survival of CCD-11Lu cells incubated with various
concentration of CAPE (0.1 mM, 1 mM, 10 mM) for 3 hours
with and without costimulation with IL-4 (10 ng/mL) and
TNF-a (10 ng/mL) for another 24 hours were all more than
90% compared with negative control. Drug concentrations
Figure 2. The effects of TNF-a and IL-4 on the induction of
eotaxin. CCD-11Lu human lung fibroblast cells were cultured
with IL-4 (10 ng/mL, 50 ng/mL) or TNF-a (10 ng/mL, 50 ng/
mL), or the combination of different concentration. Control
was represented by CCD-11Lu cells with no cytokine stimu-
lated. (*p< 0.05, compared with control experiment).
CAPEZ caffeic acid phenethyl ester; IL-4Z interleukin-4;
TNF-aZ tumor necrosis factor alpha.
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The data was shown in Fig. 1.
Synergistic induction of eotaxin production by IL-4
and TNF-a
As shown in Fig. 2, the concentrations of eotaxin in cultured
supernatants were not significantly increased when CCD-
11Lu cells were stimulated by either IL-4 or TNF-a alone.
In accordance with published data, our data showed the
cytokine combination had a clear synergistic effect. We
chose the concentration of IL-4 (10 ng/mL) and TNF-a
(10 ng/mL) for later experiments.
The effects of CAPE on eotaxin production in IL-4
and TNF-a stimulated CCD-11Lu cell
To evaluate the effect of CAPE on eotaxin secretion from
CCD-11Lu cells stimulated by IL-4 (10 ng/mL) and TNF-aFigure 3. The effects of CAPE on the induction of eotaxin.
CCD-11Lu human lung fibroblast cells were pretreated with
various concentration of CAPE (0.1 mM, 1 mM, 10 mM) for 3
hours, followed by costimulation with IL-4 (10 ng/mL) and TNF-
a (10 ng/mL) for additional 24 hours. Control was represented
by stimulated CCD-11Lu cells with no CAPE pretreatment.
(*p< 0.05, **p< 0.01; compared with control experiment).
CAPEZ caffeic acid phenethyl ester; IL-4Z interleukin-4;
TNF-aZ tumor necrosis factor alpha.(10 ng/mL), we pretreated CCD-11Lu with CAPE (0.1 mM,
1 mM, 10 mM) 3 hours before stimulation. The amount of
eotaxin production by cells stimulated by IL-4 (10 ng/mL)
and TNF-a (10 ng/mL) was calculated to be 100%, and
others were compared with it. Our results showed that
cytokine-induced eotaxin production was inhibited by CAPE
in a concentration-dependent manner. CAPE, 1 mM and
10 mM, suppressed eotaxin production by 48.13% and
18.88%, respectively (p< 0.01 and p< 0.05, respectively).Figure 4. (A) The effects of CAPE on the level of STAT6 in
nuclear extracts. CCD-11Lu lung fibroblast cells were pre-
treated with various concentration of CAPE (0.01 mM, 0.1 mM,
1 mM) for 3 hours, followed by costimulation with IL-4 (10 ng/
mL) and TNF-a (10 ng/mL) for additional 45 minutes. Control
was represented by stimulated CCD-11Lu cells with no CAPE
treatment. (*p< 0.05, compared with control experiment). (B)
The effects of CAPE on the level of p-STAT6 in nuclear extracts.
CCD-11Lu lung fibroblast cells were pretreated with various
concentration of CAPE (0.01 mM, 0.1 mM, 1 mM) for 3 hours,
followed by costimulation with IL-4 (10 ng/mL) and TNF-
a (10 ng/mL) for additional 45 minutes. Control was repre-
sented by stimulated CCD-11Lu cells with no CAPE treatment.
(*p< 0.05, compared with control experiment). The signal
intensities were analyzed by Western blotting. Western blot-
ting (30 mg protein/lane) were performed using anti-STAT6
(1:250), anti-phosphorylated STAT6 (1:500), and anti-PCNA
(1:5000) Abs, respectively. CAPEZ caffeic acid phenethyl
ester; IL-4Z interleukin-4; PCNAZ proliferating cell nuclear
antigen; STAT6Z signal transducer and activator of transcrip-
tion 6; TNF-aZ tumor necrosis factor alpha.
Suppression of CAPE in human lung fibroblast cells 439As data shown in Fig. 3, the CAPE (0.1 mM, 1 mM, 10 mM)
alone have no effect on eotaxin production.The effects of CAPE on transcriptional factor STAT6
and p-STAT6 in nucleus
We examined the signal intensity of transcriptional factor
STAT6 and p-STAT6 in the nuclear extracts of CCD-11Lu cells,
which were pretreated with CAPE with various concentration
(0.01 mM, 0.1 mM, 1 mM) for 3 hours before stimulating with
IL-4 (10 ng/mL) and TNF-a (10 ng/mL) synergistically for 45
minutes [which is the peak time of STAT6 nuclear trans-
location in our preliminary study (data not shown)]. The
signal intensities of nuclear STAT6 and p-STAT6 were cor-
rected by dividing signal intensities of nuclear proliferating
cell nuclear antigen in the same lane. The intensity from
condition stimulated by IL-4 (10 ng/mL) and TNF-a (10 ng/
mL) was calculated to be 100%, and others were compared
with it. The signal intensities of nuclear STAT6 on all condi-
tions of cells showed no statistical significance, as data
shown in Fig. 4A. Our results showed that signal intensities of
p-STAT6 were decreased at higher concentration of CAPE.
CAPE, 0.1 mM and 1 mM, suppressed the p-STAT6 signal
intensities by 53.42% and 49.07%, respectively (p< 0.05),
the data was shown in Fig. 4B.Figure 5. The effects of CAPE on the STAT6 DNA binding activit
treated with various concentration of CAPE (0.01 mM, 0.1 mM, 1 mM,
mL) and TNF-a (10 ng/mL) for additional 45 minutes. The extracts
and analyzed for binding activity by EMSA. The signal intensity of ea
system (Li-Cor Biosciences, Lincoln, NB). Control was represente
(*p< 0.05, compared with control experiment). CAPEZ caffeic aci
IL-4Z interleukin-4; STAT6Z signal transducer and activator of trThe effects of CAPE on STAT6 DNA binding activity
We assessed STAT6 DNA binding activity in the nuclear
extracts of CCD-11Lu cells, which were pretreated with
CAPE with various concentration (0.01 mM, 0.1 mM, 1 mM,
10 mM) for 3 hours before stimulating with IL-4 (10 ng/mL)
and TNF-a (10 ng/mL) synergistically for 45 minutes. The
intensity from condition stimulated by IL-4 (10 ng/mL) and
TNF-a (10 ng/mL) was calculated to be 100%, and others
were compared with it. Our results showed that DNA
binding activity of STAT6 were inhibited in the administra-
tion of CAPE before cytokine stimulation, with all experi-
mental concentration (p< 0.05). The data was shown in
Fig. 5.
Discussion
In the present study, we demonstrated that CAPE inhibited
the secretion of eotaxin as well as the STAT-6 activation
in lung fibroblast stimulated synergistically by IL-4 and
TNF-a.. To the best of our knowledge, it is the first report
involving the inhibitory effect of CAPE on STAT-6 activation.
We used IL-13 plus TNF-a as stimulator for eotaxin
secretion in the same lung fibroblast cell line (CCD-11Lu) in
our previous study.22 IL-4 and IL-13 did share many similary in nuclear extracts. CCD-11Lu lung fibroblast cells were pre-
10 mM) for 3 hours, followed by costimulation with IL-4 (10 ng/
was incubated with infrared dye-labeled oligonucleotide probe
ch lane was detected by LI-COR Odyssey infrared laser imaging
d by stimulated CCD-11Lu cells with no CAPE preatreament.
d phenethyl ester; EMSAZ electrophoretic mobility shift assay;
anscription 6; TNF-aZ tumor necrosis factor alpha.
440 Y.-T. Lin et al.activities, including being activated by STAT-6, as demon-
strated before.25 IL-4 stimulates several intracellular
signaling pathways, including the recruitment of STAT6 to
the IL-4Ra, where it is phosphorylated on tyrosine 641 by
Jac kinases, the p-STAT6 form dimers and translocates to
the nucleus to bind DNA and activate transcription. STAT6 is
tightly connected to IL-4 and IL-13 signaling and plays a key
role in Th2 polarization of the immune system.26,27
This time, we shifted IL-13 to IL-4 as part of the syner-
gistic stimulator with TNF-a. The main concern was based
on these three previous reports.17e19 Matsukura et al17 first
disclosed that IL-4 and TNF-a stimulate expression of the
eotaxin gene by activating STAT6 and NF-kB in human airway
epithelial cells. Atasoy et al18 used an actinomycin D-based
assessment that demonstrated that IL-4 and TNF-a signifi-
cantly increase eotaxin mRNA stability in human bronchial
epithelial cells. Hoeck and Woisetschlager19 showed that
the similar synergistic fashion in human fibroblast cells were
also mediated by STAT6 and NF-kB on eotaxin promoter.
Our study showed that CAPE decreased STAT6 activa-
tion and eotaxin secretion in lung fibroblast. However, our
previous study22 as well as other previous studies28,29 did
demonstrate the CAPE inhibitory effect on NF-kB activa-
tion. Recent studies revealed that eotaxin promoter
contains both binding site for NF-kB and STAT6.17,19
Moreover, a study30 showed that blocking NF-kB activity
eliminates IL-4-stimulated gene expression but not phos-
phorylation or nuclear localization of STAT-6. In our study,
the nuclear localization of STAT6 was not changed as
shown in Fig. 4A. But the STAT6 phosphorylation and
STAT6 DNA binding activity in nucleus were inhibited by
CAPE, as data shown in Fig. 4B and Fig. 5. The possible
explanation may be that the effect of CAPE on eotaxin
production could not simply be explained by inhibiting
NF-kB activity.
Recent report31 demonstrated that a novel STAT6
inhibitor, AS1517499, was able to inhibit IL-13 secretion in
cultured human bronchial smooth muscle as well as to
decrease airway hyperactivity in balb/c mice induced by
albumin sensitization. CAPE, an extract from propolis, is
a natural product used widely for many years. Based on our
preliminary result that CAPE processes inhibitory charac-
teristics on eotaxin production in human lung fibroblasts
and on phosphorylated STAT6, further studies to test its
inhibition on STAT6 and NF-kB activation is worthy.
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